On November 10, 2026 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, reported an oral presentation at the 18th Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place November 16-19, 2026, in Lisbon, Portugal.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will showcase UnigenX, an expansion of the Company’s computational discovery platform into targeted immune activation modalities, such as T cell engagers, designed to discover novel tumor-associated antigen targets and combinations for selective targeting of tumor cells.
Title: UnigenX: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation
Track: Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Speaker: Dr. Roy Granit, Head of Computational Discovery at Compugen
Date & Time: Wednesday, November 18, 2026 at 18:30 GMT
Link: PEGS Europe 2026
(Press release, Compugen, NOV 10, 2026, View Source [SID1234674583])